$AARD News
Last published 1w ago
- 1w agoAARDERASPLNTPRCTAttention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Erasca, Inc. (NASDAQ: ERAS); Planet Fitness, Inc. (NYSE: PLNT); and PROCEPT BioRobotics Corporation (NASDAQ: PRCT): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (NASDAQ:AARD): Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ:AARD) shareholders who purchased
- 1w agoAARDERASPODDPLNTAttention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Erasca, Inc. (NASDAQ: ERAS); Insulet Corporation (NASDAQ: PODD); and Planet Fitness, Inc. (NYSE: PLNT): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (NASDAQ:AARD): Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ:AARD) shareholders who purchased
- 2w agoAARDERASPSIXSMPLImportant Notice Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Erasca, Inc. (NASDAQ: ERAS); Power Solutions International, Inc. (NASDAQ: PSIX); and The Simply Good Foods Company (NASDAQ: SMPL): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (NASDAQ:AARD): Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ:AARD) shareholders who purchased
- 2w agoAARDARD-101 Update Call - AARDVARK THERAPEUTICS INCEarnings Call TranscriptsGood day. Thank you for standing by. Welcome to the AdWords Therapeutics update call. At this time, all participants are in listen-only mode. After this presentation, there will be a question and answer session. To ask a
- 2w agoAARDAardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension TrialsGlobeNewswireHERO trial terminated early (67 of 90 planned participants randomized); all efficacy data are considered exploratoryHQ-CT scores fell by Week 2 of dose escalation on ARD-101 and returned to near baseline within two
- 2w agoAARDAardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE DataGlobeNewswireClinical development of ARD-101 for hyperphagia in Prader-Willi Syndrome (PWS) may resume Aardvark will host a webcast to review available dataset from the terminated Phase 3 HERO trial and OLE trial on Friday, October
- 3w agoAARDERASGPGINUAIAttention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Erasca, Inc. (NASDAQ: ERAS); GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI); and New Era Energy & Digital, Inc. (NASDAQ: NUAI): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA , Oct. 21, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (NASDAQ:AARD): Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ:AARD) shareholders who
- 3w agoAARDBACCCBERASAttention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Bank of America Corporation (NYSE: BAC); Coastal Financial Corporation (NASDAQ: CCB); and Erasca, Inc. (NASDAQ: ERAS): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (NASDAQ:AARD): Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ:AARD) shareholders who purchased
- 3w agoAARDCCBHUBGPSIXAttention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Hub Group, Inc. (NASDAQ: HUBG); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (NASDAQ:AARD): Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ:AARD) shareholders who purchased
- 4w agoAARDCCBERASPSIXAttention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (NASDAQ:AARD): Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ:AARD) shareholders who purchased
- 4w agoAARDCCBNUAISMPLImportant Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and The Simply Good Foods Company (NASDAQ: SMPL): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (NASDAQ:AARD): Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ:AARD) shareholders who purchased
- 1mo agoAARDCCBDUOLENSGAttention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Duolingo, Inc. (NASDAQ: DUOL); and Ensign Group, Inc. (NASDAQ: ENSG): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, Oct. 10, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (NASDAQ:AARD): Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ:AARD) shareholders who purchased
- 1mo agoAARDCCBERASNUAIAttention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and New Era Energy & Digital, Inc. (NASDAQ: NUAI): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (NASDAQ:AARD): Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ:AARD) shareholders who purchased
- 1mo agoAARDGPGIPRCTSMPLImportant Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); and GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods Company (NASDAQ: SMPL): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (NASDAQ:AARD): Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ:AARD) shareholders who purchased
- 1mo agoAARDKuehn Law Encourages Investors of Aardvark Therapeutics, Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Aardvark Therapeutics, Inc. (NASDAQ:...
- 1mo agoAARDLowey Dannenberg, P.C. is Investigating Aardvark Therapeutics, Inc. (NASDAQ: AARD) for Potential Violations of the Federal Securities LawsGlobeNewswireNEW YORK, Sept. 18, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Aardvark Therapeutics, Inc. (NASDAQ:AARD)
- 1mo agoAARDBBNXERASHUBGImportant Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Beta Bionics, Inc. (NASDAQ: BBNX); Erasca, Inc. (NASDAQ: ERAS); and Hub Group, Inc. (NASDAQ: HUBG): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (NASDAQ:AARD): Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ:AARD) shareholders who
- 2mo agoAARDINVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Aardvark Therapeutics, Inc. (AARD) to Contact Law FirmPR NewswireMoore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating potential claims against the officers and directors of...
- 2mo agoAARDERASHUBGNUAIAttention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Erasca, Inc. (NASDAQ: ERAS); Hub Group, Inc. (NASDAQ: HUBG); and New Era Energy & Digital, Inc. (NASDAQ: NUAI): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (NASDAQ:AARD): Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ:AARD) shareholders who
- 2mo agoAARDShareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein ImmediatelyPR NewswireWolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a nationally recognized securities litigation law firm, announces that a securities...
- 2mo agoAARDFTKHUBGPODDImportant Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Flotek Industries, Inc. (NYSE: FTK); Hub Group, Inc. (NASDAQ: HUBG); and Insulet Corporation (NASDAQ: PODD): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (NASDAQ:AARD): Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ:AARD) shareholders who
- 2mo agoAARDShareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein ImmediatelyPR NewswireWolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a nationally recognized securities litigation law firm, announces that a securities...
- 2mo agoAARDFTKGDDYSMPLImportant Notice to Long-Term Shareholders Aardvark Therapeutics, Inc. (NASDAQ: AARD); Flotek Industries, Inc. (NYSE: FTK); GoDaddy Inc. (NYSE: GDDY); and The Simply Good Foods Company (NASDAQ: SMPL); Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (NASDAQ:AARD): Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ:AARD) shareholders who purchased
- 2mo agoAARDFTKGDDYHUBGImportant Notice to Long-Term Shareholders Aardvark Therapeutics, Inc. (NASDAQ: AARD); Flotek Industries, Inc. (NYSE: FTK); GoDaddy Inc. (NYSE: GDDY); and Hub Group, Inc. (NASDAQ: HUBG); Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (NASDAQ:AARD): Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ:AARD) shareholders who purchased
- 2mo agoAARDShareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein ImmediatelyPR NewswireWolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a nationally recognized securities litigation law firm, announces that a securities...
- 2mo agoAARDShareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein ImmediatelyGlobeNewswireNEW YORK and SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a nationally recognized securities litigation law firm, announces that a securities
- 3mo agoAARDAardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswireAssessing unblinded Phase 3 HERO and OLE data for ARD-101 in PWS in the third quarter of 2026 to support an informed determination of next steps Remains in active discussions with the FDA to support resolution of the
- 4mo agoAARDAardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSSPR NewswireOn March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced...
- 4mo agoAARDAardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSSPR NewswireOn March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced...
- 5mo agoAARDAardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSSPR NewswireOn March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced...
- 5mo agoAARDAardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSSPR NewswireOn March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced...
- 6mo agoAARDAardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical HoldGlobeNewswireSAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to
- 6mo agoAARDAardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswireARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026 $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations into mid-2027
- 7mo agoAARDAardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesGlobeNewswireVoluntary pause of the Phase 3 HERO and OLE trials evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome, further guidance on the program expected in Q2 2026 ARD-201 obesity
- 8mo agoAARDAardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi SyndromeGlobeNewswireSAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate
- 9mo agoAARDAardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate
- 9mo agoAARDAardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive OfficerGlobeNewswireSAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate
- 9mo agoAARDAardvark Therapeutics Announces Leadership AppointmentsGlobeNewswireSAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate
- 9mo agoAARDAardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi SyndromeGlobeNewswireSAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate
- 11mo agoAARDAardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi SyndromeGlobeNewswireMultiple active sites and strong US enrollment continue to support Q3 2026 timing for topline data readout Clinical trial sites in Canada and the United Kingdom have received regulatory clearance to enroll All
- 11mo agoAARDAardvark Therapeutics to Present at Upcoming Investor Conferences in DecemberGlobeNewswireSAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate
- 12mo agoAARDAardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business UpdatesGlobeNewswireAardvark has aligned with the FDA to reduce the minimum age of eligibility from 13 to 10 years old for pediatric patients in HERO, the Phase 3 trial of ARD-101 for the treatment of hyperphagia associated with
- 1y agoAARDAardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)GlobeNewswireSAN DIEGO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate
- 1y agoAARDAardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025GlobeNewswireNew preclinical results demonstrate the potential of ARD-201 in enhanced glucose control, along with preservation of lean mass, underscoring its opportunity in addressing key challenges in today's obesity treatment
- 1y agoAARDAardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)GlobeNewswireSAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics for the treatment
- 1y agoAARDAardvark Therapeutics to Present at Upcoming Investor Conferences in NovemberGlobeNewswireSAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate
- 1y agoAARDAardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeekGlobeNewswireSAN DIEGO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate
- 1y agoAARDAardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi SyndromeGlobeNewswireSAN DIEGO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate
- 1y agoAARDAardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic ForumGlobeNewswireSAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate
- 1y agoAARDAardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)GlobeNewswireSAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics for the treatment